This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Teller, M. N. Articles by Wagshul, S. F. Search for Related Content PubMed PubMed Citation Articles by Teller, M. N. Articles by Wagshul, S. F.

Host-Tumor-Drug Relationships in Experimental Chemotherapy Systems with Allogeneic and Xenogeneic Host-Tumor Combinations^*

( Division of Human Tumor Biology, Sloan-Kettering Institute for Cancer Research, and Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York)

The possible roles of host and host immunity in tumor-host-drug interrelationships were studied by comparing the effects of drugs on mouse Sarcoma 180 (S-180) growing singly in nonconditioned mice and rats and singly and bilaterally with human carcinoma H.Ep. #3 in conditioned rats. S-180 grew in 43 per cent of normal rats and in 90–100 per cent of rats conditioned with x-radiation and cortisone; generally, larger tumors grew in the latter groups. H.Ep. #3 grew in 86 per cent of the conditioned rats given implants of S-180 bilaterally. Host-conditioning did not modify the antitumor activity of thioguanine and 6-mercaptopurine against S-180 in the rat. The presence of H.Ep. #3 in the same conditioned host likewise had little or no effect on the antitumor activities of azaserine, streptimidone, actinobolin, and 6-diazo-5-oxonorleucine. A comparison of experimental chemotherapy results in conditioned and nonconditioned rats, compared with those obtained in normal mice, indicated that sensitivity of a tumor to a drug remained essentially unchanged under host-conditioning. The use of transplanted tumors in allogeneic and xenogeneic hosts and the possible effects of tumor growth on host immune mechanisms are discussed.

^* This study was supported in part by a research grant CY 3784 from the National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Maryland; in part by contract SA-43-ph-1923 and SA-43-ph-2445 from the Cancer Chemotherapy National Service Center, National Cancer Institute, Bethesda, Maryland; and in part by Grant T-47 from the American Cancer Society.

The terminology used here is that suggested by Gorer et al. (10). Briefly, syngeneic = isologous; allogeneic = homologous, and xenogeneic = heterologous.

Received 8/ 2/63.